Cargando…

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

PARP inhibitors (PARPi) have changed the management of patients with ovarian cancer and their effectiveness has been demonstrated especially in homologous recombination repair–deficient tumors. These first-generation drugs target PARP1, but also PARP2 and other family members potentially responsible...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dellavedova, Giulia, Decio, Alessandra, Formenti, Laura, Albertella, Mark R., Wilson, Joanne, Staniszewska, Anna D., Leo, Elisabetta, Giavazzi, Raffaella, Ghilardi, Carmen, Bani, Maria Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042207/ https://www.ncbi.nlm.nih.gov/pubmed/36994441 http://dx.doi.org/10.1158/2767-9764.CRC-22-0423

Ejemplares similares

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
por: Illuzzi, Giuditta, et al.
Publicado: (2022)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023)

Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium
por: Ghilardi, Carmen, et al.
Publicado: (2008)

A database of 5305 healthy Korean individuals reveals genetic and clinical implications for an East Asian population
por: Lee, Jeongeun, et al.
Publicado: (2022)

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305
por: Rosen, Elias P., et al.
Publicado: (2023)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
por: Kaye, S, et al.
Publicado: (2012)

Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2
por: Ghilardi, Carmen, et al.
Publicado: (2015)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment
por: Silini, Antonietta, et al.
Publicado: (2011)

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
por: Marley, Kevin, et al.
Publicado: (2013)

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
por: Ghilardi, Carmen, et al.
Publicado: (2022)

Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells
por: Russo, Massimo, et al.
Publicado: (2023)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Measurement of extracellular fluid carboplatin kinetics in melanoma metastases with microdialysis.
por: Blöchl-Daum, B., et al.
Publicado: (1996)

[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
por: Guibbal, Florian, et al.
Publicado: (2020)

Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours.
por: Giavazzi, R., et al.
Publicado: (1980)

Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2023)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
por: Yap, Timothy A., et al.
Publicado: (2021)

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor
por: Zhang, Peng, et al.
Publicado: (2019)

ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib
por: Wilson, Zena, et al.
Publicado: (2022)

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer
por: Coelho, Ricardo, et al.
Publicado: (2022)

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
por: Leone, Jose Pablo, et al.
Publicado: (2020)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum
por: Zhang, Peng, et al.
Publicado: (2022)

Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
por: Giavazzi, R., et al.
Publicado: (1988)

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305
por: Kapadia, Shashi N., et al.
Publicado: (2018)

Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
por: Pretto, Francesca, et al.
Publicado: (2014)

Correction: Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle
por: Pretto, Francesca, et al.
Publicado: (2016)

Endoplasmic reticulum oxidoreductin 1‐alpha deficiency and activation of protein translation synergistically impair breast tumour resilience
por: Varone, Ersilia, et al.
Publicado: (2022)

Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells
por: Sargazi, Saman, et al.
Publicado: (2019)

Extensive necrosis of visceral melanoma metastases after immunotherapy
por: Stoeter, David, et al.
Publicado: (2008)

Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone
por: Fallarino, Francesca, et al.
Publicado: (2009)

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics
por: Engert, Florian, et al.
Publicado: (2016)

Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft
por: Chaudhury, Anumita, et al.
Publicado: (2012)

Treatment with Tie2-siRNA in combination with carboplatin suppresses the growth of Ishikawa human endometrial carcinoma cell xenografts in vivo
por: GUO, FEIFEI, et al.
Publicado: (2013)

Imaging of Treatment Response to the Combination of Carboplatin and Paclitaxel in Human Ovarian Cancer Xenograft Tumors in Mice Using FDG and FLT PET
por: Munk Jensen, Mette, et al.
Publicado: (2013)

A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin
por: Fan, Dengxuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m40pu0l16veu9gcrs3n0aakj5h